Thyroid function in patients with Alzheimer disease: Implications on response to anticholinesterase treatment

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 4, 2006, Pages 242-247

  Kapaki, Elisabeth ^a   Paraskevas, George P ^a   Mantzou, Emily ^b   Papapostolou, Apostolos ^a   Alevizaki, Maria ^b   Vassilopoulos, Demetris ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; Donepezil; Thyroid function tests

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; LIOTHYRONINE; THYROID ANTIBODY; THYROID PEROXIDASE; THYROTROPIN; THYROXINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FREE THYROXINE INDEX; HORMONE RELEASE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MALE; PRIORITY JOURNAL; STANDARD; THYROID FUNCTION; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; THYROID FUNCTION TESTS; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 33845403730     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000213856.89613.59     Document Type: Article

References (44)

1. Thompson CC, Potter GB. Thyroid hormone action in neural development. Cerebral Cortex. 2000;10:939-945.
2. Smith JW, Evans AT, Costall B, et al. Thyroid hormones, brain function and cognition: a brief review. Neurosci Biobehav Rev. 2002;26:45-60.
3. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Alzheimer's disease: genetic aspects and associated clinical disorders. Ann Neurol. 1983;14:507-515.
4. Breteler MM, van Duijn CM, Chandra V, et al. Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol. 1991;20(suppl 2):S36-S42.
5. Lopez O, Huff FJ, Martinez AJ, et al. Prevalence of thyroid abnormalities is not increased in Alzheimer's disease. Neurobiol Aging. 1989;10:247-251.
6. Yoshimasu F, Kokmen E, Hay ID, et al. The association between Alzheimer's disease and thyroid disease in Rochester, Minnesota. Neurology. 1991;41:1745-1747.
7. Kalmijn S, Mehta KM, Pols HAP, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol. 2000;53:733-737.
8. van der Cammen TJM, Raso FM, de Jager M-C, et al. Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population. J Am Geriatr Soc. 2003;51:884.
9. van Osch LA, Hogervorst E, Combrinck M, et al. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology. 2004;62:1967-1971.
10. Sunderland T, Tariot PN, Mueller EA, et al. TRH stimulation test in dementia of the Alzheimer type and elderly controls. Psychiatry Res. 1985;16:269-275.
11. Molchan SE, Lawlor BA, Hill JL, et al. The TRH stimulation test in Alzheimer's disease and major depression: relationship to clinical and CSF measures. Biol Psychiatry. 1991;30:567-576.
12. Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 1993;77:1130-1134.
13. Thomas DR, Hailwood R, Harris B, et al. Thyroid status in senile dementia of the Alzheimer type (SDAT). Acta Psychiat Scand. 1987;76:158-163.
14. Genovesi G, Paolini P, Marcellini L, et al. Relationship between autoimmune thyroid disease Rand Alzheimer's disease. Panminerva Med. 1996;38:61-63.
15. Ewins DL, Rossor MN, Butler J, et al. Association between autoimmune thyroid disease and familial Alzheimer's disease. Clin Endocrinol (Oxf). 1991;35:93-96.
16. Martinez M, Fernandez-Vivancos E, Frank A, et al. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res. 2000;869:216-219.
17. Emilien G, Beyreuther K, Masters CL, et al. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol. 2000;57:454-459.
18. Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Exp Rev Neurotherap. 2001;1:61-69.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
20. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med. 1979;9:139-145.
22. Royston JP. An extension of Shapino and Wilk's W Test for Normality to large samples. Appl Statist. 1982;31:115-124.
23. Godfrey K. Comparing the means of several groups. In: Bailar JC III, Mosteller F, eds. Medical Uses of Statistics. 2nd ed. Boston: NEJM Books; 1992:233-257.
24. Kjellman BF, Thorell LH, Orhagen T, et al. The hypothalamic-pituitary- thyroid axis in depressive patients and healthy subjects in relation to the hypothalamic-pituitary-adrenal axis. Psychiatry Res. 1993;47:7-21.
25. Maes M, Meltzer HY, Cosyns P, et al. An evaluation of basal hypothalamic-pituitary-thyroid axis function in depression: results of a large scales and controlled study. Psychoneuroendocrinology. 1993;18:607-620.
26. Joffe RT, Sokolov STH, Singer W. Thyroid hormone treatment of depression. Thyroid. 1995;5:235-239.
27. Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol. 1998;138:1-9.
28. Stern RA, Davis JD, Rogers BL, et al. Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer dementia. Cogn Behav Neurol. 2004;17:219-223.
29. Lopez OL, Rabin BS, Huff FJ, et al. Serum autoantibodies in patients with Alzheimer's disease and vascular dementia and in nondemented control subjects. Stroke. 1992;23:1078-1083.
30. Mappouras DG, Philippou G, Haralambous S, et al. Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease. Clin Exp Immunol. 1995;100:336-343.
31. Kapaki E, Paraskevas GP. The cognitive effects of cholinesterase inhibitor treatment in every-day practice. Curr Med Res Opin. 2005;21:871-875.
32. Maayan ML, Volpert EM, From A. Acetylcholine and norepinephrine: compared actions thyroid metabolism. Endocrinology. 1983;112:1358-1362.
33. Grunditz T, Sundler F. Autonomic Nervous Control: Adrenergic, Cholinergic, and Peptidergic regulation. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid. 7th ed. Philadelphia: Lippincott-Raven; 1996:247-251.
34. Stopa EG, Volicer L, Kuo-Leblanc V, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol. 1999;58:29-39.
35. Kalsbeek A, Fliers E, Franke AN, et al. Functional connections between the suprachiasmatic nucleus and the thyroid gland as revealed by lesioning and viral tracing techniques in the rat. Endocrinology. 2000;141:3832-3841.
36. Joffe RT, Singer W. The effect of tricyclic antidepressants on basal thyroid hormone levels in depressed patients. Pharmacopsychiatry. 1990;23:67-69.
37. Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychopharmacol. 2000;3:149-165.
38. Campos-Barros A, Meinhold H, Stula M, et al. The influence of desipramine on thyroid hormone metabolism in rat brain. J Pharmacol Exp Ther. 1994;268:1143-1152.
39. Campos-Barros A, Meinhold H, Köhler R, et al. The effects of desipramine on thyroid hormone concentrations in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1995;351:469-474.
40. Leonard JL, Köhrle J. Intracellular pathways of iodothyronine metabolism. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid. 7th ed. Philadelphia: Lippincott-Raven; 1996:125-161.
41. Bauer M, London ED, Silverman DH, et al. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003;36(suppl 3):S215-S221.
42. Sampaolo S, Campos-Barros A, Mazziotti G, et al. Increased cerebrospinal fluid levels of 3,3′,5′-triiodothyronine in patients with Alzheimer's disease. J Clin Endocrinol Metab. 2005;90:198-202.
43. Lahiri DK. Reversibility of the effect of tacrine on the secretion of the beta-amyloid precursor protein in cultured cells. Neurosci Lett. 1994;181:149-152.
44. Kapaki E, Ilias I, Paraskevas GP, et al. Thyroid function in patients with Alzheimer's disease treated with cholinesterase inhibitors. Acta Neurobiol Exp. 2003;63:389-392.